AbbVie stock declines as it hits a 20-day low
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 05 Jan 26
Source: SeekingAlpha
AbbVie Inc (ABBV) experienced a price drop of 3.96%, hitting a 20-day low during regular trading hours.
This decline occurs amid broad market strength, with the Nasdaq-100 up 0.89% and the S&P 500 up 0.61%. Despite the overall positive market conditions, AbbVie is facing challenges related to its upcoming earnings report and the ongoing impact of the Humira patent cliff, which has raised concerns among investors.
The stock's performance reflects a sector rotation as investors reassess their positions in the pharmaceutical sector, particularly in light of AbbVie's recent struggles despite its strong dividend yield and market cap.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 253.26 USD with a low forecast of 218.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
15 Buy
7 Hold
0 Sell
Moderate Buy
Current: 220.770
Low
218.00
Averages
253.26
High
289.00
Current: 220.770
Low
218.00
Averages
253.26
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
